Skip to content
In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk
All contributors

Onconephrology contributor

Marasco, Wayne A

Primarily Cellular therapy renal effects#35 of 46 recognized
  • #1 in Cellular therapy renal effects
5
Clinical papers
457
Citations (iCite)
0 / 4
First / senior author
2016–2025
Active years

Output over time

Clinical corpus papers per year — peak 2 in 2024.

  • 2016: 1 paper
  • 2021: 1 paper
  • 2024: 2 papers
  • 2025: 1 paper
20162025

Subfield mix

Clinical papers by onconephrology subfield (a paper can count in more than one).

Cellular therapy renal effects5

Frequent co-authors

Other recognized contributors who most often share corpus papers with Marasco (shared-paper count).

Suarez, Eloah Rabello3

Verify

Representative recent papers, and this author’s full PubMed bibliography.

PMID 40774229 (opens PubMed in a new tab)PMID 38491381 (opens PubMed in a new tab)PMID 38195534 (opens PubMed in a new tab)PMID 33191639 (opens PubMed in a new tab)PMID 27145284 (opens PubMed in a new tab)All papers on PubMed

A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.